Skip to main content
Erschienen in: Clinical Rheumatology 1/2023

27.09.2022 | Case Based Review

Tophaceous gout in a young man with Gitelman syndrome: a case report with an overview

verfasst von: Leila Rouached, Emna Hannech, Riadh Jeribi, Olfa Saidane, Aicha Ben Tekaya, Selma Bouden, Rawdha Tekaya, Linda Belhaj Kacem, Ines Mahmoud, Soumaya Rammeh, Leila Abdelmoula

Erschienen in: Clinical Rheumatology | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Abstract

Gitelman syndrome represents the clinical manifestations of inactivation of the Slc12a3 genes encoding the thiazide-sensitive sodium chloride cotransporter and the Trpm6-Mg genes encoding the magnesium transporters in the distal convoluted tubule. In fact, the biochemical findings resemble those with thiazide diuretics such as hypokalemia, hypomagnesaemia, hypocalciuria, metabolic alkalosis, and low normal blood pressure. He is usually associated with calcium pyrophosphate deposition. Serum uricemia level is rarely affected in Gitelman syndrome. We aimed to report a rare association of chronic gout with Gitelman syndrome, hence the interest of our case. We describe a 29-year-old male patient with a history of Gitelman syndrome associated with articular gout including pelvic localization. We provided pictorial evidence of extensive and diffuse monosodium urate deposition in articular and periarticular structures to confirm the gout origin. A literature review illustrates 4 reported cases of Gitelman syndrome associated with gout. The gender distribution was equal with a mean age of 40 years.
Key Points
• Gouty arthritis and Gitelman syndrome is a rare association.
• Gitelman syndrome may be a new risk factor for the development of gout, due to its thiazide-like effect.
Literatur
1.
Zurück zum Zitat Wilson L, Saseen JJ (2016) Gouty Arthritis: A Review of Acute Management and Prevention. Pharmacother J Hum Pharmacol Drug Ther 36:906–922CrossRef Wilson L, Saseen JJ (2016) Gouty Arthritis: A Review of Acute Management and Prevention. Pharmacother J Hum Pharmacol Drug Ther 36:906–922CrossRef
3.
Zurück zum Zitat Ben Salem C, Slim R, Fathallah N, Hmouda H (2017) Drug-induced hyperuricaemia and gout. Rheumatology 56(5):679–688 Ben Salem C, Slim R, Fathallah N, Hmouda H (2017) Drug-induced hyperuricaemia and gout. Rheumatology 56(5):679–688
4.
Zurück zum Zitat Pizzorno JE, Murray MT, Joiner-Bey H (2016) Gout. The Clinician’s Handb Nat Med 347–354 Pizzorno JE, Murray MT, Joiner-Bey H (2016) Gout. The Clinician’s Handb Nat Med 347–354
5.
Zurück zum Zitat Casatta L, Ferraccioli GF, Bartoli E (1997) Hypokalaemic alkalosis, acquired Gitelman’s and Bartter’s syndrome in chronic sialoadenitis. Rheumatology 36:1125–1128CrossRef Casatta L, Ferraccioli GF, Bartoli E (1997) Hypokalaemic alkalosis, acquired Gitelman’s and Bartter’s syndrome in chronic sialoadenitis. Rheumatology 36:1125–1128CrossRef
6.
Zurück zum Zitat Troster SM, Raizman JE, Rubin L (2016) An Unusual Case of Gout in a Young Woman with Gitelman Syndrome. J Rheumatol 43:2085–2087CrossRef Troster SM, Raizman JE, Rubin L (2016) An Unusual Case of Gout in a Young Woman with Gitelman Syndrome. J Rheumatol 43:2085–2087CrossRef
7.
Zurück zum Zitat Mou L, Wu F (2021) Simultaneous Homozygous Mutations in SLC12A3 and CLCNKB in an Inbred Chinese Pedigree. Genes 12:369CrossRef Mou L, Wu F (2021) Simultaneous Homozygous Mutations in SLC12A3 and CLCNKB in an Inbred Chinese Pedigree. Genes 12:369CrossRef
8.
Zurück zum Zitat Lawrence RC, Felson DT, Helmick CG, Arnold LM, Choi H, Deyo RA et al (2008) Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II Arthritis Rheum 58:26–35CrossRef Lawrence RC, Felson DT, Helmick CG, Arnold LM, Choi H, Deyo RA et al (2008) Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II Arthritis Rheum 58:26–35CrossRef
9.
Zurück zum Zitat Dehlin M, Jacobsson L, Roddy E (2020) Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors. Nat Rev Rheumatol juill 16(7):380–390CrossRef Dehlin M, Jacobsson L, Roddy E (2020) Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors. Nat Rev Rheumatol juill 16(7):380–390CrossRef
10.
Zurück zum Zitat Chen-Xu M, Yokose C, Rai SK, Pillinger MH, Choi HK (2019) Contemporary Prevalence of Gout and Hyperuricemia in the United States and Decadal Trends: The National Health and Nutrition Examination Survey 2007–2016. Arthritis Rheumatol Hoboken NJ juin 71(6):991–999CrossRef Chen-Xu M, Yokose C, Rai SK, Pillinger MH, Choi HK (2019) Contemporary Prevalence of Gout and Hyperuricemia in the United States and Decadal Trends: The National Health and Nutrition Examination Survey 2007–2016. Arthritis Rheumatol Hoboken NJ juin 71(6):991–999CrossRef
11.
Zurück zum Zitat Girish G, Glazebrook KN, Jacobson JA (2013) Advanced Imaging in Gout. Am J Roentgenol 201:515–525CrossRef Girish G, Glazebrook KN, Jacobson JA (2013) Advanced Imaging in Gout. Am J Roentgenol 201:515–525CrossRef
12.
Zurück zum Zitat Tekaya R, Tekaya AB, Saidane O, Said HB, Gaja A, Sahli H et al (2018) Tophaceous hip gouty arthritis revealing asymptomatic axial gout. Egypt Rheumatol 40:209–212CrossRef Tekaya R, Tekaya AB, Saidane O, Said HB, Gaja A, Sahli H et al (2018) Tophaceous hip gouty arthritis revealing asymptomatic axial gout. Egypt Rheumatol 40:209–212CrossRef
13.
Zurück zum Zitat Gitelman HJ, Graham JB, Welt LG (1966) A new familial disorder characterized by hypokalemia and hypomagnesemia. Trans Assoc Am Physicians 79:221–235 Gitelman HJ, Graham JB, Welt LG (1966) A new familial disorder characterized by hypokalemia and hypomagnesemia. Trans Assoc Am Physicians 79:221–235
14.
Zurück zum Zitat Simon DB, Nelson-Williams C, Johnson Bia M, Ellison D, Karet FE, Morey Molina A et al (1996) Gitelman’s variant of Barter’s syndrome, inherited hypokalaemic alkalosis, is caused by mutations in the thiazide-sensitive Na–Cl cotransporter. Nat Genet 12:24–30CrossRef Simon DB, Nelson-Williams C, Johnson Bia M, Ellison D, Karet FE, Morey Molina A et al (1996) Gitelman’s variant of Barter’s syndrome, inherited hypokalaemic alkalosis, is caused by mutations in the thiazide-sensitive Na–Cl cotransporter. Nat Genet 12:24–30CrossRef
15.
Zurück zum Zitat Lemmink HH, Knoers NV, Károlyi L, van Dijk H, Niaudet P, Antignac C et al (1998) Novel mutations in the thiazide-sensitive NaCl cotransporter gene in patients with Gitelman syndrome with predominant localization to the C-terminal domain. Kidney Int 54:720–730CrossRef Lemmink HH, Knoers NV, Károlyi L, van Dijk H, Niaudet P, Antignac C et al (1998) Novel mutations in the thiazide-sensitive NaCl cotransporter gene in patients with Gitelman syndrome with predominant localization to the C-terminal domain. Kidney Int 54:720–730CrossRef
16.
Zurück zum Zitat Koçkara AŞ, Candan F, Hüzmeli C, Kayataş M, Alaygut D (2013) Gitelman’s syndrome associated with chondrocalcinosis: a case report. Ren Fail 35:1285–1288CrossRef Koçkara AŞ, Candan F, Hüzmeli C, Kayataş M, Alaygut D (2013) Gitelman’s syndrome associated with chondrocalcinosis: a case report. Ren Fail 35:1285–1288CrossRef
17.
Zurück zum Zitat Lin SH, Cheng NL, Hsu YJ, Halperin ML (2004) Intrafamilial phenotype variability in patients with Gitelman syndrome having the same mutations in their thiazide-sensitive sodium/chloride cotransporter. Am J Kidney Dis Off J Natl Kidney Found 43:304–312CrossRef Lin SH, Cheng NL, Hsu YJ, Halperin ML (2004) Intrafamilial phenotype variability in patients with Gitelman syndrome having the same mutations in their thiazide-sensitive sodium/chloride cotransporter. Am J Kidney Dis Off J Natl Kidney Found 43:304–312CrossRef
18.
Zurück zum Zitat Favero M, Calò LA, Schiavon F, Punzi L (2011) Bartter’s and Gitelman’s diseases. Best Pract Res Clin Rheumatol 25:637–648CrossRef Favero M, Calò LA, Schiavon F, Punzi L (2011) Bartter’s and Gitelman’s diseases. Best Pract Res Clin Rheumatol 25:637–648CrossRef
19.
Zurück zum Zitat Cipolletta E, Di Matteo A, Filippucci E, Grassi W (2020) Calcium Pyrophosphate Deposition Disease in a Patient with Familial Hypokalemia-Hypomagnesemia (Gitelman’s-Syndrome): A Case Report - CPPD in Gitelman’s syndrome. Ultraschall Med 41(6):695–697CrossRef Cipolletta E, Di Matteo A, Filippucci E, Grassi W (2020) Calcium Pyrophosphate Deposition Disease in a Patient with Familial Hypokalemia-Hypomagnesemia (Gitelman’s-Syndrome): A Case Report - CPPD in Gitelman’s syndrome. Ultraschall Med 41(6):695–697CrossRef
20.
Zurück zum Zitat Chotard E, Blanchard A, Ostertag A, Latourte A, Gailly G, Frochot V et al (2022) Calcium pyrophosphate crystal deposition in a cohort of 57 patients with Gitelman syndrome. Rheumatology (Oxford) 61(6):2494–2503CrossRef Chotard E, Blanchard A, Ostertag A, Latourte A, Gailly G, Frochot V et al (2022) Calcium pyrophosphate crystal deposition in a cohort of 57 patients with Gitelman syndrome. Rheumatology (Oxford) 61(6):2494–2503CrossRef
21.
Zurück zum Zitat Meyer WJ 3rd, Gill JR Jr, Bartter FC (1975) Gout as a complication of Bartter’s syndrome. A possible role for alkalosis in the decreased clearance of uric acid. Ann Intern Med 83:56–59CrossRef Meyer WJ 3rd, Gill JR Jr, Bartter FC (1975) Gout as a complication of Bartter’s syndrome. A possible role for alkalosis in the decreased clearance of uric acid. Ann Intern Med 83:56–59CrossRef
22.
Zurück zum Zitat Moriwaki Y, Yamamoto T, Takahashi S, Tsutsumi Z, Hada T (2001) An atypical case of primary renal tubular hypokalaemic metabolic alkalosis with chronic tophaceous gout. Clin Rheumatol 20(5):372–375CrossRef Moriwaki Y, Yamamoto T, Takahashi S, Tsutsumi Z, Hada T (2001) An atypical case of primary renal tubular hypokalaemic metabolic alkalosis with chronic tophaceous gout. Clin Rheumatol 20(5):372–375CrossRef
23.
Zurück zum Zitat Shahzad MA, Mukhtar M, Ahmed A, Ullah W, Saeed R, Hamid M (2019) Gitelman Syndrome: A Rare Cause of Seizure Disorder and a Systematic Review. Case Rep Med 2019:1–8CrossRef Shahzad MA, Mukhtar M, Ahmed A, Ullah W, Saeed R, Hamid M (2019) Gitelman Syndrome: A Rare Cause of Seizure Disorder and a Systematic Review. Case Rep Med 2019:1–8CrossRef
Metadaten
Titel
Tophaceous gout in a young man with Gitelman syndrome: a case report with an overview
verfasst von
Leila Rouached
Emna Hannech
Riadh Jeribi
Olfa Saidane
Aicha Ben Tekaya
Selma Bouden
Rawdha Tekaya
Linda Belhaj Kacem
Ines Mahmoud
Soumaya Rammeh
Leila Abdelmoula
Publikationsdatum
27.09.2022
Verlag
Springer International Publishing
Erschienen in
Clinical Rheumatology / Ausgabe 1/2023
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-022-06361-2

Weitere Artikel der Ausgabe 1/2023

Clinical Rheumatology 1/2023 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Ist Fasten vor Koronarinterventionen wirklich nötig?

Wenn Eingriffe wie eine Koronarangiografie oder eine Koronarangioplastie anstehen, wird häufig empfohlen, in den Stunden zuvor nüchtern zu bleiben. Ein französisches Forscherteam hat diese Maßnahme hinterfragt.

Typ-2-Diabetes: Ernährungsunsicherheit vervierfacht Risiko für schwere Hypoglykämien

04.06.2024 Typ-2-Diabetes Nachrichten

Wenn ältere Menschen mit Typ-2-Diabetes Schwierigkeiten beim Beschaffen und Zubereiten von Mahlzeiten haben, geht dies mit einem deutlich gesteigerten Risiko für schwere Hypoglykämien einher.

Mehr Brustkrebs, aber weniger andere gynäkologische Tumoren mit Levonorgestrel-IUS

04.06.2024 Levonorgestrel Nachrichten

Unter Frauen, die ein Levonorgestrel-freisetzendes intrauterines System (IUS) verwenden, ist die Brustkrebsrate um 13% erhöht. Dafür kommt es deutlich seltener zu Endometrium-, Zervix- und Ovarialkarzinomen.

GLP-1-Agonist Semaglutid wirkt kardio- und nephroprotektiv

03.06.2024 Semaglutid Nachrichten

Der GLP-1-Agonist Semaglutid hat in der FLOW-Studie bewiesen, dass sich damit die Progression chronischer Nierenerkrankungen bei Patienten mit Typ-2-Diabetes bremsen lässt. Auch in kardiovaskulärer Hinsicht war die Therapie erfolgreich.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.